en · de · es · fr · pt
glossary-desk.peptides7250.com › Data › Identity And Research Background — Beginner to Advanced

Identity And Research Background — Beginner to Advanced

By Editorial Desk · published 2026-07-05 · last reviewed 2026-07-28 · Data

This is a working overview of freeze-thaw cycle, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.

Identity And Research Background

BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.

The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.

Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.

Research Literature and Evidence Gaps

Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.

Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.

Bpc-157 at a glance

PropertyValueNotes
Amino acid count15 residuesSynthetic pentadecapeptide chain
SequenceGEPPPGKPADDAGLVSingle-letter amino acid code
Molecular formulaC62H98N16O22Free peptide, without counter-ion
Theoretical massApproximately 1419.5 daltonsVaries slightly with adducts and counter-ions
OriginFragment of a human gastric juice proteinSource of the BPC designation

Handling, Stability, and Quality Checks

The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.

Related pages on this site

Stability, Storage, and Analytical Testing

Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.

A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.

Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.

Origin and Peptide Identity

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Further detail

== History == Biomatrica was founded by scientists, Judy Müller-Cohn, PhD, and Rolf Müller, PhD, in 2004. Prior to founding Biomatrica, both had worked many years in San Diego's biotechnology industry. Müller-Cohn had previously worked at Digital Gene Technologies and Mycogen/ Dow Agrosciences, whilst Müller had worked on the HIV Core Program Project Grant at San Diego's Scripps Research Institute. Biomatrica initially developed ambient temperature storage reagents for DNA and RNA. The company's core technology was inspired by the phenomenon of anhydrobiosis, the ability of some organisms to hibernate in a desiccated state during dry periods, and then reanimate upon contact with water. Focusing on microscopic, desert-dwelling creatures called Tardigrades, which undergo anhydrobiosis for up to 120 years, Biomatrica identified how to chemically mimic the mechanism of anhydrobiosis. Following stabilization at room temperature with Biomatrica's chemical reagents, biological specimens could be rehydrated for subsequent studies with the addition of a few drops of water. Since 2012, the company has become increasingly focused on its pre-analytic collection and assay stabilization service businesses described below. In October 2018 Biomatrica was acquired by the Madison, Wisconsin-based molecular diagnostics and cancer screening company Exact Sciences Corporation for $20 million.

Formaldehyde appears to be a useful probe in astrochemistry due to prominence of the 110←111 and 211←212 K-doublet transitions. It was the first polyatomic organic molecule detected in the interstellar medium. Since its initial detection in 1969, it has been observed in many regions of the galaxy. Because of the widespread interest in interstellar formaldehyde, it has been extensively studied, yielding new extragalactic sources. A proposed mechanism for the formation is the hydrogenation of CO ice:

=== Livestock feed === One of the major uses of soybeans globally is as livestock feed, predominantly in the form of soybean meal. In the European Union, for example, though it does not make up most of the weight of livestock feed, soybean meal provides around 60% of the protein fed to livestock. In the United States, 70 percent of soybean production is used for animal feed, with poultry being the number one livestock sector of soybean consumption. The American Soybean Association estimates that over 90% of U.S. soybeans are used as animal feed and 97% of soybean meal feeds livestock and poultry. Spring grasses are rich in omega-3 fatty acids, whereas soy is predominantly omega-6. The soybean hulls, which mainly consist of the outer coats of the beans removed before oil extraction, can also be fed to livestock and whole soybean seeds after processing.

Sources: en.wikipedia.org

Supporting material

== External links == Clinical Laboratory Improvement Amendments (CLIA), Centers for Medicare & Medicaid Services (CMS) CLIA Regulations Assessment Workgroup, CDC Clinical Laboratory Improvement Advisory Committee (CLIAC) CLIA Laboratory Lookup, CMS S&C's Quality, Certification and Oversight Reports (QCOR)

Very strong: H1 Strong: 5-HT2A, α1-adrenergic Moderate: D2, mACh Weak: 5-HT2C, D1, α2-adrenergic In spite of its atypical nature and different profile of activity, trimipramine has been shown in head-to-head clinical studies to possess equivalent effectiveness to other antidepressants, including but not limited to other TCAs (e.g., amitriptyline, imipramine, doxepin, amineptine), tetracyclic antidepressants (TeCAs) (e.g., maprotiline), monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, isocarboxazid), and selective serotonin reuptake inhibitors (e.g., fluoxetine). In addition, trimipramine has been found to possess greater anxiolytic effects than other TCAs such as amitriptyline and doxepin in head-to-head comparisons. Indeed, its prominent anxiolytic effects have been said to distinguish it from most other TCAs. The atypicality of trimipramine in relation to its lack of monoamine reuptake inhibition is described as challenging the monoamine hypothesis of depression. The major metabolite of trimipramine, desmethyltrimipramine, is considered to possess pharmacological activity similar to that of other demethylated tertiary amine TCA variants.

=== Polysaccharides === Certain compounds found in mushrooms, primarily polysaccharides, can up-regulate the immune system and may have anti-cancer properties. For example, beta-glucans such as lentinan have been shown in laboratory studies to stimulate macrophage, NK cells, T cells and immune system cytokines and have been investigated in clinical trials as immunologic adjuvants.

=== Planets === Though many other civilisations in the Culture books live on planets, the Culture as currently developed has little direct connection to on-planet existence. Banks has written that he presumes this to be an inherent consequence of space colonisation, and a foundation of the liberal nature of the Culture. A small number of home worlds of the founding member-species of the Culture receive a mention in passing, and a few hundred human-habitable worlds were colonised (some of them terraformed) before the Culture elected to turn towards artificial habitats, preferring to keep the planets it encounters wild. Since then, the Culture has come to look down on terraforming as inelegant, ecologically problematic and possibly even immoral. Less than one per cent of the population of the Culture lives on planets, and many find the very concept somewhat bizarre. This attitude is not absolute though; in Consider Phlebas, some Minds suggest testing a new technology on a "spare planet" (knowing that it could be destroyed in an antimatter explosion if unsuccessful). One could assume – from Minds' usual ethics – that such a planet would have been lifeless to start with. It is also quite possible, even probable, that the suggestion was not made in complete seriousness.

Sources: en.wikipedia.org

Notes from published material

PHGDH is allosterically regulated by its downstream product, L-serine. This feedback inhibition is understandable considering that 3-phosphoglycerate is an intermediate in the glycolytic pathway. Given that PHGDH represents the committed step in the production of serine in the cell, flux through the pathway must be carefully controlled. L-serine binding has been shown to exhibit cooperative behavior. Mutants that decreased this cooperativity also increased in sensitivity to serine's allosteric inhibition, suggesting a separation of the chemical mechanisms that result in allosteric binding cooperativity and active site inhibition. The mechanism of inhibition is Vmax type, indicating that serine affects the reaction rate rather than the binding affinity of the active site. Although L-serine's allosteric effects are usually the focus of regulatory investigation, it has been noted that in some variants of the enzyme, 3-phosphoglycerate dehydrogenase is inhibited at separate positively charged allosteric site by high concentrations of its own substrate.

EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid), also known as egtazic acid (INN, USAN), is an aminopolycarboxylic acid, a chelating agent. It is a white solid that is related to the better known EDTA. Compared to EDTA, it has a lower affinity for magnesium, making it more selective for calcium ions. It is useful in buffer solutions that resemble the environment in living cells where calcium ions are usually at least a thousandfold less concentrated than magnesium. The pKa for binding of calcium ions by tetrabasic EGTA is 11.00, but the protonated forms do not significantly contribute to binding, so at pH 7, the apparent pKa becomes 6.91. See Qin et al. for an example of a pKa calculation. EGTA has also been used experimentally for the treatment of animals with cerium poisoning and for the separation of thorium from the mineral monazite. EGTA is used as a compound in elution buffer in the protein purification technique known as tandem affinity purification, in which recombinant fusion proteins are bound to calmodulin beads and eluted out by adding EGTA. EGTA is often employed in dentistry and endodontics for the removal of the smear layer.

== Limitations of model == AIDA, like other model-based approaches, is not sufficiently accurate to be used for individual patient simulation or glycemic prediction. Therefore, as the program makes clear, it is not intended for insulin therapy planning and can only be used for teaching, self-learning, demonstration, or research purposes. While the AIDA software can simulate a wide variety of insulin dosage and diet (nutrition) adjustments, it should be stressed that the purpose of AIDA is to create a learning environment for communicating and training intuitive thinking when dealing with such adjustments. In this respect AIDA appears most of use for recreating clinical situations in diabetes care, rather than trying to predict best outcome.

The Don Cossacks flag 3:4 was inaugurated during the Don Cossacks assembly in Novocherkassk, Don Republic, on 4 May 1918 under chiefing of Ataman Pyotr Krasnov. The flag has three colours: blue, yellow, and red. The flag is similar to that of the Ukrainian State, also established in 1918, which the Don Republic bordered to its west.

== Signs and symptoms == Initially, the symptoms of biliary atresia are indistinguishable from those of neonatal jaundice, a usually harmless condition commonly seen in infants. However, infants with biliary atresia develop progressive conjugated jaundice, pale white stools, dark urine, and an enlarged palpable liver. Some infants fail to thrive as there will be a degree of fat and fat-soluble vitamin malabsorption (e.g. Vitamin K). This may cause a bleeding tendency. Eventually, and usually after 2 months, cirrhosis with portal hypertension will develop. If left untreated, biliary atresia can lead to liver failure. Unlike other forms of jaundice, however, biliary-atresia-related cholestasis mostly does not result in kernicterus, a form of brain damage resulting from liver dysfunction. This is because in biliary atresia, the liver, although diseased, is still able to conjugate bilirubin, and conjugated bilirubin is unable to cross the blood–brain barrier.

Sources: en.wikipedia.org

Frequently asked questions

Is BPC-157 a naturally occurring compound?

The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.

Which species have been studied most?

Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.

Is it an approved drug?

It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.

Is BPC-157 approved for medical use?

It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.

Network